No Data
PAVmed Shares Are Trading Higher After the Company Announced It and Lucid Diagnostics Submitted Complete Clinical Evidence for Its Esoguard Esophageal DNA Test.
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard Esophageal DNA Test
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Cantor Fitzgerald Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Cuts Target Price to $2
Lucid Diagnostics Price Target Cut to $2.00/Share From $3.00 by Cantor Fitzgerald
Maxim Group Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Maintains Target Price $4
No Data
No Data